Loading clinical trials...

Gene Expression That Predicts Radiation Exposure in Humans | Clinical Trials | Clareo Health

COMPLETED

Gene Expression That Predicts Radiation Exposure in Humans

NCT03123133•DxTerity Diagnostics

Summary

To verify and validate a biodosimetry test for determining absorbed ionizing radiation dose by analyzing gene expression signatures of blood samples collected from patients treated with Total Body Irradiation (TBI).

Detailed Description

In order validate the performance of DxTerity's Radiation Biodosimetry Test (RBT) system, several clinical centers will provide controlled, de-identified blood samples and associated clinical information to DxTerity Diagnostics (DxTerity). Variations in dose and frequency of delivery in TBI protocols are expected between the clinical centers and this has been accounted for in the study design. Samples from up to 200 participants will be collected via this protocol. Blood samples for this study will be collected from radiation therapy patients receiving TBI as part of a therapeutic regimen from the site. Blood samples (up to 4 mL per time point) may be obtained at the time of routine blood collection; participation in this biomarker study will not affect any aspect of patient treatment. Study samples will be obtained prior to, during, and post-radiation treatment regimen. Associated clinical information will be collected from the subject's medical record, as well.

Eligibility

Age

2 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. Male and female patients age 2 or older.
•2. Weigh at least 13kg (30lbs), and in the opinion of the investigator, are healthy enough to participate in study activities.
•3. Evidence of a personally signed and dated informed consent/assent document indicating that the subject or a legally acceptable representative (parent(s)/legal guardian) has been informed of all pertinent aspects of the study.
•4. Diseases treated with HSCT, including malignant and nonmalignant diseases.
•5. Planned fractionated total body irradiation (TBI) as part of clinical care with a cumulative dose ≥6 Gy or a single dose between 1.5 and 3.0 Gy.

Exclusion Criteria

•1. Subjects who have received chemotherapy within 21 days prior to TBI.
•2. Concurrent chemotherapy with Fludarabine or an investigational product
•3. Cytokine inhibitor or cytokine-inducer therapy within 30 days prior to and during the irradiation regimen
•4. Subjects who have received GCSF within 30 days prior to TBI
•5. Participants, who in the opinion of the investigator, may not be able to comply with the requirements of the study.

Locations (3)

City of Hope

Duarte, California, United States

University of California, Los Angeles, Radiation Oncology

Los Angeles, California, United States

Fred Hutch Cancer Research Center

Seattle, Washington, United States

Key Dates

Start Date

April 6, 2017

Primary Completion Date

April 17, 2020

Completion Date

July 14, 2020

Last Updated

April 21, 2021

Enrollment

151

ACTUAL participants

Conditions

Total Body Irradiation

BuCy Vs. TBICy for Allo-HSCT in T-ALL Patients

NCT06673459

T-Cell Lymphocytic LeukemiaALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION+2 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: April 21, 2021Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions